Cost-Effectiveness Analysis of Angiotensin-II Receptor Blocker in Hypertension Patients at Tertiary Hospital


  • Weena Promprasert, Pharm., M.P.A., M.S.


Cost-Effectiveness Analysis, Angiotensin-II Receptor Blockers, Hypertension


Background: During 2017 to 2019, angiotensin-II Receptor Blocker- treat patients accounted for 9.5 million baht in each year at this tertiary hospital. Essential drug was most frequently prescribed as health policy directed. Utilization cost of non-essential drug was doubled whereas essential drug usage was approximately fourfold to non-essential drug. Cost-effectiveness analysis will represent which drug is more worthiness to manage drug procurement. Objective: To evaluate the cost- effectiveness of achieving JNC8 with angiotensin-II receptor blockers compare between essential drug and non-essential drug. Method: Cost- effectiveness of azilsartan, candesartan, irbesartan, losartan, olmesartan and valsartan were obtained from medical claims database between January 1, 2017 and December 30, 2019. Patients with a diagnosis of hypertension in the 6- month baseline and ARB–free during baseline were included. The effectiveness was conducted in terms of number of patients who reached JNC8 BP goals within 24 weeks after the first date of ARB claim. The attributable costs were defined as the cost of ARB class and other classes that associated with hypertension treatment i.e. ACE inhibitors, beta-blockers, calcium channel blockers and diuretics. Cost- effectiveness analysis was compared to losartan. SPSS version 25.0 was used in this study. Result: 2198 patients were identified (mean age 57 ± 13 year, 38.0 % male, body mass index 27 ± 5). Comorbidity diseases were mostly for dyslipidemia (E78) 33.94% and diabetes (E119) 9.19%.Based on antihypertensive efficacy versus losartan within 24 weeks, low dose of candesartan and irbesartan reduced SBP significantly (p <.05) while olmesartan and valsartan reduced DBP significantly (p < .001). High dose of azilsartan and olmesartan reduced significant SBP and DBP respectively (p < .05, p < .001).The most benefit was valsartan of low dose and candesartan of high dose. This study was taken from real world data so the difference of heterogeneity such as type and number of co-morbidities diseases might cause of uncertainty and also the number of patients in each drug could not desirable. Conclusion: Overall valsartan was favored of the most cost- effectiveness for low dose and candesartan for high dose compared to losartan as of essential drug comparator.


Download data is not yet available.


Thai Hypertension Society. 2019 Thai Guidelines on the treatment of Hypertension. Trickthink Printing;2019.p.1-23.

World Health Report 2002: Reducing risks, promoting healthy life. Geneva, Switzerland: World Health Organization; 2002.

Chobnian AV, Bakris GL, Black HR, Cushman WC, Green LA,Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-5.

James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA2014; 311:507-20.

Upakdee N. Health economics. Phitsanulok: Ratanasuwan Printing; 2018. p.61-81.

Sakthong P. Measurement of clinical effect utility. Journal of Medical Association of Thailand 2008; 91 Suppl.2:s42-52.

Non Communicable Diseases Data 2019. Division of Non Communicable Diseases, Ministry of Public Health;2019.

Chanhyuan Park, Guijing Wang, Jefferey M Durthaler, Jing Fang.Cost-effectiveness analyses of antihypertensive medicines:a systematic review. Am J Prev Med 2017;6: s131-42.

Oparis S, Williams D.Chrysant SG, Marbury TC, Neutel J.Comparative efficay of olmesartan, losrtan, valsartan and irbesartan in the control of essential hypertension. J Clin Hypertens 2001;3:283-91.

Giles TD, Oparis S, Silfani TN, Wang A, Walker JF. Compariso of increasing doses of olmesartan medoxomil,losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens 2007;9:187-95.

Boersma C, Voors AA,Visser ST, de Jong-van den Berg LT,Postma MJ. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data. Am J Cardiovasc Drugs. 2010; 10:49-54.

White WB, Cuadra RH, Lloyd E, Bakris GL, Kupfer S. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type2 diabetes and prediabetes. J Hypertens 2016; 34:788-97.



How to Cite

วีณา พร้อมประเสริฐ ภ.บ.,รป.ม.,วท.ม. Cost-Effectiveness Analysis of Angiotensin-II Receptor Blocker in Hypertension Patients at Tertiary Hospital. j dept med ser [Internet]. 2021 Mar. 10 [cited 2022 Aug. 14];45(4):154-61. Available from:



Original Article